Last updated on December 2019

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity


Brief description of study

The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. The participant's chance of getting semaglutide or placebo is the same. The participant will get the study medicine in a pen. The participants will need to use the pen to inject the study medicine in a skinfold once a week. The study will last for about 2.5 to 5 years. Participants will have up to 25 clinic visits with the study doctor.

Clinical Study Identifier: NCT03574597

Find a site near you

Start Over

Novo Nordisk Investigational Site

Heidelberg Heights, Australia
2.46miles
  Connect »

Novo Nordisk Investigational Site

Melbourne, Australia
6.21miles
  Connect »